Clinical trials: Post-ERCP Pancreatitis
Pancreatitis, Cholangiopancreatography, Endoscopic Retrograde
The Optimal Dose of Indomethacin Suppository for Preventing Post-ERCP Pancreatitis
This study is a single-center, randomized, single-blind, parallel controlled clinical study to explore the optimal dose of postoperative indomethacin suppository for the prevention of post-ERCP pancreatitis.
- Conditions
- Pancreatitis, Cholangiopancreatography, Endoscopic Retrograde, Indomethacin
- Trial name
- NCT06031363
- Testing
- Indomethacin Suppository
- Where
- China
- Volunteers
- 192 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Post ERCP Pancreatitis
Intramuscular Diclofenac in the Prevention of Post-ERCP Pancreatitis
Pancreatitis is one of the major complications of ERCP. It has been shown that NSAIDs are potent inhibitors of phospholipase A2, activity which is increased in pancreatitis.
- Trial name
- NCT01717599
- Testing
- Diclofenac, normal saline
- Where
- South Korea
- Volunteers
- 343 people
- Sponsor
- Yonsei University
Pancreatitis, Acute
COX-2 Inhibitor to Prevent Post-ERCP Pancreatitis
Acute pancreatitis is the most common and feared complication of ERCP, occurring after 1% to 30% of procedures. Since 2012, a multicenter RCT was published in NEJM, indomethacin use in high risk patients was considered a…
- Trial name
- NCT02964403
- Testing
- Cox-2, Indomethacin
- Volunteers
- 2,700 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
ERCP, Biliary Disease Tract
Is Needle Knife Fistulotomy An Effective First Step Strategy For All ERCPs?
Participants in this study will be undergoing a procedure called an endoscopic retrograde cholangiopancreatography (ERCP). This procedure is most commonly performed to help treat conditions affecting specific areas of the…
- Conditions
- ERCP, Biliary Disease Tract, Biliary Disease
- Trial name
- NCT03698266
- Testing
- Needle knife fistulotomy
- Where
- Canada
- Volunteers
- 84 people
- Sponsor
- Lawrence Charles Hookey
Post-ERCP Acute Pancreatitis
Evaluation of Post-ERCP Pain as a Predictor for Post-ERCP Pancreatitis
Pancreatitis is the most common complication after ERCP, although its frequency varies significantly depending on the study from < 2% up to 40%.
- Trial name
- PEP-PREPARE (NCT04770857)
- Testing
- Visual analogue scale
- Where
- Switzerland
- Volunteers
- 1,000 people
- Sponsor
- Nicola Frei
Common Bile Duct Stones
Early Precut Versus Pancreatic Stent for Post-ERCP Pancreatitis
BACKGROUND: The most common complication of endoscopic retrograde cholangiopancreatography (ERCP) is pancreatitis. Precut sphincterotomy has been regarded as a risk factor.
- Trial name
- NCT02497872
- Testing
- Biliary stone removal
- Volunteers
- 100 people
- Sponsor
- Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
Post-ERCP Acute Pancreatitis
Rectal Indomethacin vs Intravenous Ketorolac
Endoscopic retrograde cholangiopancreatography (ERCP) is an essential procedure that can be complicated by post-ERCP pancreatitis (PEP). Indomethacin and ketorolac are two medications used to prevent PEP.
- Trial name
- NCT05664074
- Testing
- Rectal indomethacin, IV ketorolac
- Where
- United States
- Volunteers
- 192 people
- Sponsor
- David Vitale MD
Cholangitis, Post-ERCP Acute Pancreatitis
Optimal Placement Duration of Pancreatic Duct Stent
A randomized controlled trial to determine the optimal placement duration of pancreatic duct stents (PDS) inserted during ERCP: 2 vs 4 weeks
- Conditions
- Cholangitis, Post-ERCP Acute Pancreatitis, Stent Dislodgement
- Trial name
- NCT04691674
- Testing
- Endoscopy
- Where
- South Korea
- Volunteers
- 122 people
- Sponsor
- DongGuk University
Post-ERCP Acute Pancreatitis
Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
Acute pancreatitis is the most common and feared complication of ERCP, occurring after 1% to 30% of procedures. Since 2012, a multicenter RCT was published in NEJM, indomethacin use in high risk patients was considered a…
- Trial name
- Indomethacin (NCT02002650)
- Testing
- Pre-ERCP rectal Indomethacin, Post-operational Rectal Indomethacin
- Where
- 6 sites in China
- Volunteers
- 2,600 people
- Sponsor
- Air Force Military Medical University, China
Post-ERCP Acute Pancreatitis
Randomized Trial of Rectal Indomethacin and Papillary Spray of Epinephrine Versus Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
This research is being done to see if using a combination of rectal indomethacin and epinephrine spray during endoscopy, can prevent pancreatitis that may occur after ERCP (a type of gastrointestinal endoscopy).
- Trial name
- INDIEH (NCT02116309)
- Testing
- Rectal Indomethacin, Epinephrine
- Where
- 4 sites in United States, India
- Volunteers
- 948 people
- Sponsor
- Johns Hopkins University
Pancreatitis
A Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP Pancreatitis
Determine if IV ketorolac is an effective agent in the prevention of post-ERCP pancreatitis. Determine if IV ketorolac provides improved post-procedure analgesia.
- Trial name
- NCT02465138
- Testing
- Ketorolac
- Where
- 2 sites in United States
- Sponsor
- University of California, San Francisco
Post-ERCP Acute Pancreatitis, Epinephrine
Effect of Papillary Epinephrine Spraying for the Prevention of Post-ERCP Pancreatitis in Patients Received Octreotide
Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the most common complication with high costs, significant morbidity and even mortality.
- Trial name
- NCT03756116
- Testing
- Epinephrine sprayed on the papilla, Saline sprayed on the papilla
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- The Second Hospital of Nanjing Medical University
Pancreatitis
Post ERCP Pancreatitis Prevention in Average Risk Patients
Diclophenac potassium and ceftazidime are commercially available drugs that are used in various clinical situations. They are safe and known for years.
- Trial name
- NCT01784445
- Testing
- Ceftazidime
- Where
- Croatia
- Volunteers
- 124 people
- Sponsor
- University Hospital Rijeka
Post-ERCP Acute Pancreatitis
PAN-PROMISE to Detect Post-ERCP Pancreatitis Symptoms
The aim of this study is to use a validated patient-reported outcome measure to evaluate how many patients have symptoms of pancreatitis after ERCP and how it correlates with their quality of life and productivity.
- Trial name
- PAN-PROMISE (NCT05310409)
- Where
- 2 sites in United States
- Volunteers
- 700 people
- Sponsor
- University of Pennsylvania
ERCP
Indian National Study to Assess Incidence and Severity of Post-ERCP Pancreatitis After Following SOP
Endoscopic retrograde cholangiopancreatography (ERCP) is an indispensable therapeutic procedure in the management of a wide spectrum of pancreaticobiliary disorders, including choledocholithiasis, benign and malignant biliary…
- Trial name
- INSPIRE (NCT07329790)
- Volunteers
- 2,366 people
- Sponsor
- Asian Institute of Gastroenterology, India
Post-ERCP Pancreatitis
Pharmacological Prophylaxis of Post- Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
The investigators aimed to perform a comparative study, evaluating the efficacy of three prophylactic approaches aiming to reduce the risk of post-ERCP pancreatitis, using pharmacologic agents with different mechanisms of action…
- Trial name
- NCT03708458
- Testing
- indomethacin suppository, N-acetylcysteine (NAC)
- Where
- Romania
- Volunteers
- 250 people
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
Post-ERCP Acute Pancreatitis
7 cm vs. 5 cm Pancreatic Stents for the Prevention of Post-ERCP Pancreatitis in High-risk Patients
Acute pancreatitis is the most common complication of endoscopic retrograde cholangiopancreatography (ERCP). The incidence of post-ERCP pancreatitis (PEP) is estimated to be 10% to 15% in high-risk patients.
- Trial name
- NCT04145336
- Testing
- 5cm 5-Fr PDS, 7cm 5-Fr PDS, Indomethacin
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Air Force Military Medical University, China
Healthy
Combination of Rectal Indomethacin and Pancreatic Duct Stenting Versus Indomethacin Alone in Preventing PEP
Rectal indomethacin and pancreatic duct (PD) stenting (PDS) are recommended for the prevention of post-ERCP pancreatitis (PEP). However, the effects of the combination of the two methods on preventing PEP are controversial.
- Trial name
- NCT04340687
- Testing
- Pancreatic duct stenting
- Where
- China
- Volunteers
- 664 people
- Sponsor
- Air Force Military Medical University, China
Common Bile Duct Stone, Malignant Hepatobiliary Neoplasm
Primary Needle Knife Fistulotomy Versus Conventional Cannulation Method
The aim of this study are to evaluate the feasibility of needle knife fistulotomy (NKF) as an initial procedure for biliary access in patients with biliary disease who are at increased risk for post-endoscopic retrograde…
- Conditions
- Common Bile Duct Stone, Malignant Hepatobiliary Neoplasm, Biliary Stricture, Pancreatic Diseases
- Trial name
- NCT02916199
- Testing
- cannulation of ampulla of Vater
- Where
- 7 sites in South Korea
- Volunteers
- 207 people
- Sponsor
- Gangnam Severance Hospital
Post-ERCP Acute Pancreatitis
Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis
This research is being done to see if using oral tacrolimus before endoscopy, can prevent pancreatitis that may occur after ERCP (a type of gastrointestinal endoscopy).
- Trial name
- INTRO (NCT05252754)
- Testing
- Tacrolimus capsule, Rectal Indomethacin
- Where
- 5 sites in United States, India and 1 more
- Volunteers
- 4,874 people
- Sponsor
- Johns Hopkins University